Biomakers

Executive Summary

Biomakers is an Argentine biotechnology company founded in 2020 that aims to address unmet needs in oncology, immunology, and autoimmune disorders through next-generation biologics and cell-based therapies. Leveraging a proprietary protein-engineering platform, the company is developing novel antibody-drug conjugates (ADCs) and engineered T-cell products targeting solid tumors and autoimmune conditions. With $25 million raised and a team of 50–200 employees, Biomakers is currently in the preclinical stage, positioning itself as a potential partner for global pharmaceutical companies. The company's early-stage pipeline and innovative platform technology suggest significant upside potential if clinical development succeeds. However, as a preclinical entity, it faces typical risks including regulatory hurdles and funding requirements for advancing into clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Completion of lead ADC preclinical toxicology studies70% success
• Q4 2026IND filing for lead oncology candidate40% success
• Q2 2026Strategic partnership or licensing deal with a major pharma25% success